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ABSTRACT
High-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation
(HSCT) is currently being evaluated for the control of severe autoimmune diseases. The addition of antithy-
mocyte globulin (ATG) to high-dose chemoradiotherapy in the high-dose immunosuppressive therapy regi-
men and CD34 selection of the autologous graft may induce a higher degree of immunosuppression compared
with conventional autologous HSCT for malignant diseases. Patients may be at higher risk of transplant-
related complications secondary to the immunosuppressed state, including Epstein-Barr virus (EBV)–associ-
ated posttransplantation lymphoproliferative disorder (PTLD), but this is an unusual complication after
autologous HSCT. Fifty-six patients (median age, 42 years; range, 23-61 years) with either multiple sclerosis
(n  26) or systemic sclerosis (n  30) have been treated. The median follow-up has been 24 months (range,
2-60 months). Two patients (multiple sclerosis, n  1; systemic sclerosis, n  1) had significant reactivations
of herpesvirus infections early after HSCT and then developed aggressive EBV-PTLD and died on days 53
and 64. Multiorgan clonal B-cell infiltrates that were EBV positive by molecular studies or immunohistology
were identified at both autopsies. Both patients had positive screening skin tests for equine ATG (Atgam) and
had been converted to rabbit ATG (Thymoglobulin) from the first dose. Of the other 54 patients, 2 of whom
had partial courses of rabbit ATG because of a reaction to the intravenous infusion of equine ATG, only 1
patient had a significant clinical reactivation of a herpesvirus infection (herpes simplex virus 2) early after
HSCT, and none developed EBV-PTLD. The T-cell count in the peripheral blood on day 28 was 0/L in all
4 patients who received rabbit ATG; this was significantly less than in patients who received equine ATG
(median, 174/L; P  .001; Mann-Whitney ranked sum test). Although the numbers are limited, the time
course and similarity of the 2 cases of EBV-PTLD and the effect on day 28 T-cell counts support a relationship
between the development of EBV-PTLD and the administration of rabbit ATG. The differences between
equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this
regimen without further study.
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INTRODUCTION
Pilot studies were performed of high-dose immuno-
suppressive therapy (HDIT) followed by transplantation
of autologous CD34-selected peripheral blood stem cells
(PBSC) to obtain safety and preliminary efﬁcacy data in
patients with severe autoimmune diseases. The HDIT
regimen included high-dose cyclophosphamide (Cy) and
total-body irradiation (TBI). However, the regimen was
modiﬁed from the conventional high-dose chemoradio-
therapy regimens used for the treatment of malignancies
to reduce the severity of regimen-related toxicities but
yet maximize the degree of immunosuppression. The
dose of TBI was of moderate intensity (800 cGy), the
autologous PBSC graft was CD34 selected, and equine
antithymocyte globulin (ATG) was administered before
and after transplantation for in vivo T-cell depletion. If
patients had positive skin tests or adverse infusional re-
actions to equine ATG (Atgam; Pharmacia, Peapack,
NJ), rabbit ATG (Thymoglobulin; Sangstat, Lyon,
France) was administered instead.
Lymphoproliferative disorders associated with the
Epstein-Barr virus (EBV) occur with congenital or ac-
quired immunodeﬁciency disorders but are most often
seen in immunosuppressed patients after solid organ or
allogeneic hematopoietic stem cell transplantation
(HSCT). A lymphoproliferative disorder occurs when
there is a failure to control proliferation of EBV-infected
B cells because of impaired T-cell immunity. EBV-asso-
ciated posttransplantation lymphoproliferative disorder
(PTLD) is an infrequent complication after high-dose
chemoradiotherapy and autologous HSCT for malig-
nant diseases. In 1 single-center study, it was reported
that there were 4 (0.7%) cases among 612 patients re-
viewed [1]. There have been other infrequent case re-
ports of EBV-PTLD after autologous HSCT, but none
to date have been reported after HDIT for patients with
severe autoimmune diseases [2-8]. As a result of the
modiﬁcations to the high-dose chemoradiotherapy, in-
cluding lymphocyte depletion by CD34 selection and
the addition of ATG before and after HSCT, patients
may be profoundly immunosuppressed. We report here
2 cases of EBV-PTLD after autologous HSCT that
were associated with an increased degree of immunosup-
pression after rabbit ATG was substituted for equine
ATG in the HDIT regimen for patients with a positive
skin test to the equine product.
METHODS
Patients
Fifty-six patients were enrolled on 2 multicenter
phase II studies coordinated by the Fred Hutchinson
Cancer Research Center (FHCRC) of HDIT and
HSCT for multiple sclerosis (MS) and severe systemic
sclerosis (SSc) from January 1997 to September 2002
[9,10]. The primary objective of the pilot studies was
to assess the safety of the HDIT regimen and the
transplantation of autologous CD34-selected stem
cells. Secondary end points included disease response,
safety of mobilization with granulocyte colony-stim-
ulating factor (G-CSF), and immunologic recovery.
Patients were enrolled at FHCRC (n  35), the Uni-
versity of Michigan (n  5), the University of Ne-
braska (n  4), Loma Linda University (n  3),
Wayne State University (n  3), Washington Univer-
sity (n  2), the Texas Transplant Institute (n  2),
the University of Colorado (n  1), and City of Hope
National Medical Center (n  1). The stem cell col-
lection procedure and the HDIT regimen were ini-
tially the same for both protocols. Because of positive
skin tests, 2 patients were treated with only rabbit
ATG instead of equine ATG. Two other patients had
infusion reactions to equine ATG initially and then
were later switched to rabbit ATG. Protocols were
reviewed and approved by the Institutional Review
Ofﬁce of the FHCRC (Seattle, WA). All patients
consented to participate in the protocols, according to
the institutional requirements.
Treatment and Supportive Care
PBSC were mobilized in the outpatient depart-
ment with subcutaneous G-CSF at 16 g/kg/d (Fig-
ure 1). The ﬁrst apheresis was done on day 4. G-CSF–
mobilized PBSC products were CD34-selected by
using an Isolex 300I (Baxter, Deerﬁeld, IL) with tar-
gets of 3.5  106 CD34 cells per kilogram [11].
Unmodiﬁed PBSC (3.0  106 CD34 cells per
kilogram) were also stored for potential backup use.
The autologous cell product was evaluated after CD34
selection for content of CD34 cells and T cells
(CD3) by ﬂow cytometry. Cells were cryopreserved
by using standard techniques [12]. Because of a ﬂare of
MS during mobilization of the fourth patient, routine
administration of prednisone was started with the ﬁfth
MS patient enrolled in that study. Prednisone 1 mg/
kg/d was administered 1 day before the start of G-
CSF and was continued for 10 days. Prednisone was
not used during PBSC mobilization of SSc patients.
HDIT included fractionated TBI delivered as
200 cGy fractions, 2 fractions per day, on day 5 and
day 4, for a total dose of 800 cGy; Cy 60 mg/kg
intravenously on days 3 and 2; and equine ATG
(Atgam) 15 mg/kg/d intravenously on days 5, 3,
1, 1, 3, and 5. Patients who had a positive skin
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test or infusional reactions to equine ATG were
switched to rabbit ATG (Thymoglobulin) at 2.5 mg/
kg/d on the same schedule as the equine ATG. Day 0
was designated as the day of PBSC infusion. Methyl-
prednisolone 1 mg/kg intravenously was given with
each dose of ATG. TBI was administered from either
opposing dual cobalt 60 sources or linear accelerators
at dose rates of 7 to 15 cGy/min. TBI from the dual
opposed cobalt 60 sources was administered without
lung shielding, which was not required because of the
patient positioning in the radiation ﬁeld. If TBI was
administered from a linear accelerator, lung shielding
was used to limit whole-lung doses to approximately
650 cGy. After the eighth SSc patient, all patients in
this study received lung shielding to ensure that the
lungs received a total dose of no more than 200 cGy.
This was accomplished with the use of a partial trans-
mission block. G-CSF 5 g/kg/d intravenously or
subcutaneously was given from day 0 until the abso-
lute neutrophil count was 500/L for 3 days. In
the MS study, prednisone 0.5 mg/kg/d was given as
a single dose from day 7 to day 21 and then
was tapered and completed at day 30 to prevent
neurologic complications during engraftment. In the
SSc study, as protection against lung toxicity and to
standardize steroid therapy after HDIT, prednisone
(0.5 mg/kg/d) was given from the start of conditioning
until day 30 and tapered over 1 month. Patients
were hospitalized from the start of conditioning
therapy until there was neutrophil engraftment (abso-
lute neutrophil count 500/L) and resolution of
major toxicities. Infection prophylaxis included tri-
methoprim-sulfamethoxazole for Pneumocystis carinii
[13], ﬂuconazole for candida [14], and acyclovir for
herpes simplex virus and varicella-zoster virus (1 year).
Patients were monitored for cytomegalovirus (CMV)
reactivation, and if positive, preemptive therapy with
ganciclovir was started [15].
Diagnosis of EBV-PTLD
Biopsy specimens were evaluated morphologically
and with immunocytochemistry stains by using CD20
and latent membrane protein 1 (LMP1). Clonality was
assessed by  and  light chain restriction. Molecular
studies were done for EBV by in situ hybridization for
EBV-encoded RNA (EBER). Copy numbers of EBV
DNA were assessed in patient serum by polymerase
chain reaction as previously described [16].
Immune Recovery
Lymphocyte subsets were enumerated by using
3-color ﬂow cytometry as described [17-20]. Brieﬂy,
blood mononuclear cells (MNCs) were stained with
mouse monoclonal antibodies conjugated to ﬂuoro-
chromes (ﬂuorescein isothiocyanate, phycoerythrin,
and phycoerythrin plus cyanin 5). Flow cytometry
data were acquired by using a FACSCalibur ﬂow cy-
tometer (BD Biosciences, San Jose, CA) and were
analyzed with Winlist software (Verity, Topsham,
ME). T cells were deﬁned as CD3 MNCs. B cells
were deﬁned as MNCs expressing CD19 or CD20 and
not brightly expressing CD3, CD10, CD13, CD14,
CD16, CD34, or CD56. Natural killer (NK) cells
were deﬁned as MNCs expressing CD16 or CD56 and
not expressing CD3 or CD14. Absolute counts (per
unit volume) were calculated as percentages (deter-
mined by ﬂow cytometry) multiplied by absolute lym-
phocyte plus monocyte counts (determined by the
clinical hematology laboratory) and divided by 100.
Statistics
Outcomes are reported as of November 2002 and
are based on the last follow-up of each patient. Me-
dians and ranges are reported unless otherwise speci-
ﬁed. A Mann-Whitney ranked sum test was used for
comparing peripheral blood CD3 T-cell numbers at
day 28 in patients who received rabbit ATG with
those that received equine ATG.
RESULTS
Patient Characteristics
Of the 56 patients enrolled in the study, 35 pa-
tients were female (Table 1). Thirty patients had SSc,
Figure 1. Mobilization and treatment schema for patients with MS
and SSc receiving autologous HSCT after HDIT. MS patients were
given prednisone during mobilization to prevent ﬂares.
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and 26 patients had MS. The median age of the
patient population was 42 years (range, 23-61 years).
The median duration of the disease was 45 months
(range, 4-277 months) before HDIT. The median
follow-up for all patients was 24 months (range, 2-60
months). All patients were scheduled to receive Atgam
as part of the HDIT. However, because of positive
skin tests to equine ATG, 2 patients were treated with
only rabbit ATG (total dose, 12.5 and 15 mg/kg,
respectively). Two other patients who had infusion
reactions with equine ATG were then switched to
rabbit ATG (total dose, 10 mg/kg each). Patients who
received rabbit ATG did not receive more pretrans-
plant immunosuppressive therapy compared with the
patients who did not receive rabbit ATG. One patient
with a positive skin test to equine ATG was treated
with Cy and TBI only.
PBSC Collections and Engraftment
The median number of aphereses required for
collection of the required number of CD34 cells for
HSCT and backup was 3 (range, 2-8; Table 2). One
patient with SSc failed mobilization with G-CSF and
required remobilization with the combination of Cy
and G-CSF. The median number of CD34 cells
infused on day 0 was 4.1 (range, 2.5-8.2)  106/kg.
The median purity of the CD34-selected cell product
was 88% (54%-99%). The median number of B cells
(30 evaluable patients) and T cells (41 evaluable pa-
tients) in the autologous graft after CD34 selection
was 18.7 (range, 1.91-14.60)  104 CD19/20 cells
per kilogram and 3.2 (range, 0.1-16.8)  104 CD3
cells per kilogram, respectively. Three of the 4 pa-
tients who received rabbit ATG were evaluated for the
T-cell content of the autologous grafts after CD34
selection, and all had values greater than the median
for the overall group. The median time to neutrophil
(500/L) and platelet (20,000/L with transfusion
support) engraftment was 9 days (range, 6-13 days)
and 9 days (range, 5-25 days), respectively. One pa-
tient with SSc did not recover platelet counts at 6
months after autologous HSCT; this was related to
the development of a consumptive thrombocytopenia.
EBV-PTLD after HDIT and Autologous Stem Cell
Transplantation
Two of the 56 patients developed reactivation of
herpesvirus infections and then were diagnosed with
EBV-PTLD at day 50 and 61 after autologous HSCT.
These 2 patients received only rabbit ATG at a total
dose of 12.5 and 15 mg/kg. The 2 patients who re-
ceived equine ATG initially and then rabbit ATG did
not develop any signiﬁcant opportunistic infections or
EBV-PTLD.
Case 1. A 28-year-old woman had been well until
she was diagnosed with diffuse SSc at 27 months
before HDIT. The disease process involved the skin,
gastrointestinal tract, joints, and lungs. She had a
history of hypertension requiring treatment with ni-
fedipine, captopril, and labetalol. Recurrence of a
pericardial effusion led to the opening of a pericardial
window. Renal function was normal. The patient had
progressive lung disease with a decrease in CO2-dif-
fusing capacity of the lungs from 83% to 66% over the
previous 6 months. The serologic studies for the an-
tinuclear antibody were positive at a titer of 1:5120,
and those for Scl-70 were negative. Other medications
at baseline before transplantation were prednisone
and methotrexate.
After consenting to participate in the study and
undergoing baseline evaluation, the patient underwent
mobilization and HDIT according to the protocol as
previously outlined. Because there was a positive skin
test to the equine ATG, rabbit ATG (2.5 mg/kg per
dose) was administered instead for 5 doses. The day
5 dose of rabbit ATG was not given. The patient
received 4.2  106 CD34-selected cells per kilogram
on day 0, and additional unselected PBSCs were cryo-
preserved. The patient engrafted uneventfully on day
10 and was discharged from the hospital. On day
Table 1. Patient Characteristics (n  56)
Variable Data
Age, y, median (range) 42 (23-61)
Sex (male/female) 21/35
Disease
Multiple sclerosis 26
Systemic sclerosis 30
Follow-up, mo, median, (range) 24 (3-60)
Type of antithymocyte globulin
Equine 51
Rabbit 2
Both 2
Neither 1
Table 2. Characteristics of the Grafts and Engraftment
Variable Median Range
Evaluable
Patients (n)
Mobilization and grafts
Number of aphereses* 3 2-8 56
CD34 cells  106/kg 4.12 2.46-8.24 56
Purity (%) 88 75-99 56
T cells  104/kg 3.20 0-25.20 41
B cells  104/kg 18.7 1.91-14.60 30
Engraftment
Days to ANC > 500/L 9 6-13 56
Days to platelets >
20 000/L 9 5-25 56†
ANC indicates absolute neutrophil count.
*Backup autografts were also collected.
†One patient did not have recovery of platelet counts after HSCT
and was considered not evaluable for determining the range.
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38, the patient was readmitted to the hospital with
severe stomatitis secondary to a herpes simplex (type
1) infection that was resistant to acyclovir. Foscarnet
and hyperalimentation were started. On day 48,
diffuse bilateral interstitial inﬁltrates developed in the
lung that were associated with respiratory failure. The
patient had an endotracheal tube placed and was me-
chanically ventilated. Bronchoscopy with bronchoal-
veolar lavage was nondiagnostic. On day 61, EBV-
PTLD was suspected on the basis of the development
of hepatosplenomegaly and B-cell lymphocytosis,
which was lambda light chain predominant. The
backup autologous graft (unselected cryopreserved pe-
ripheral blood cells) was reinfused to restore T-cell
immunity. This was followed by the administration of
rituximab 375 mg/m2. The lymphocyte count de-
creased, but the patient’s clinical condition worsened,
and she died on day 64. Core needle biopsies were
performed of the lung, liver, spleen, and bone marrow
as a limited autopsy. A diffuse large B-cell inﬁltrate
was observed in all the tissues sampled. The inﬁltrate
was CD20 and lambda light chain predominant, and
EBV studies, including immunocytochemistry stains
for EBV-LMP1, were positive.
Case 2. A 57-year-old woman was diagnosed with
MS 5 years before transplantation after presenting
with sensory and motor neurological dysfunction.
Magnetic resonance imaging of the brain showed 5
white matter lesions in the periventricular region and
corona radiata bilaterally. Oligoclonal bands were
present in the cerebrospinal ﬂuid. The patient was
started on 	-interferon. Secondary progressive disease
had developed by 3 years before transplantation. 	-In-
terferon was continued, and glatiramer acetate was
started. The patient’s disease continued to progress,
and methotrexate was added to the treatment regimen
1 year before transplantation. Before transplantation,
the patient had an expanded disability status scale
score of 6.0 that had increased by 1.0 point from the
previous year. Eligibility for the protocol was con-
ﬁrmed with 2 separate assessments by a study and an
independent neurologist.
After consenting to the study, the patient under-
went PBSC collection, and HDIT was administered
according to the protocol as previously outlined (Fig-
ure 1). There was a positive skin test to equine ATG,
so rabbit ATG (2.5 mg/kg per dose) was administered
for 6 doses. The patient received 3.4  106 CD34-
selected cells per kilogram on day 0. Neutrophil en-
graftment occurred on day 10. In the second week
after the transplantation, the patient became CMV
antigenemia positive and developed pneumonitis and
gastroenteritis. The washings from a bronchoalveolar
lavage at bronchoscopy were positive for CMV.
Treatment was initiated with ganciclovir, cidofovir,
and CMV immunoglobulin. There was gradual im-
provement in the patient’s clinical condition and a
decrease in the pulmonary inﬁltrates. On day42, the
serum copy number of EBV DNA per microgram of
DNA was 76. On day 49, the patient developed
increasing dyspnea, with an increase in pulmonary
inﬁltrates and the development of cervical lymphade-
nopathy. The serum copy number of EBV DNA per
microgram of DNA was 13,000. On day50, a biopsy
of the cervical lymph node was performed, which
showed a diffuse large B-cell lymphoma. Flow studies
on a cell suspension from the lymph node were posi-
tive for CD20, CD19, HLA-DR, and  light chain.
Immunocytochemistry studies for EBV-LMP1 and
EBER in situ hybridization were both positive. Treat-
ment was started with rituximab 375 mg/m2 and Cy 1
g/m2. Despite treatment and mechanical ventilation,
there was progressive respiratory failure, and the pa-
tient died on day 53.
At autopsy, there was widespread dissemination of
large B-cell lymphoma throughout multiple organs,
including lung, liver, gastrointestinal tract, adrenal
glands, kidney, and bladder. Rare cells in the lung
were positive by immunocytochemistry for CMV an-
tigen.
Peripheral Blood T Cells
The absolute CD3 T-cell counts in the peripheral
blood of 44 of the 56 study patients at 1 month after
transplantation were determined. The CD3 T-cell
count was 0/L in all 4 patients who received rabbit
ATG in whole or in part during HDIT (Table 2). The
median CD3 T-cell count was 174/L (range, 16-
4371/L) in the 40 patients who did not receive rabbit
ATG. This was signiﬁcantly different from the patients
who received rabbit ATG (P 
 .001). In the 2 patients
who received rabbit ATG and survived to day 80, the
CD3 T-cell counts had recovered to the median count
observed on day 80 in the equine ATG group. B- and
NK-cell counts in the 4 patients who received rabbit
ATG were comparable to those in the patients in the
equine ATG group (Table 3).
DISCUSSION
More than 90% of humans become infected with
EBV. After infection, EBV persists within the body in
resting memory B cells. The EBV genome encodes
nearly 100 viral proteins during viral replication,
whereas only 10 are expressed in latently infected B
cells in vitro. Latently infected B cells in the blood of
healthy carriers express only EBER, LMP2, and, in
some studies, EBV nuclear antigen 1 [21]. In B cells
from EBV-associated lymphoproliferative diseases, all
the latency genes are expressed, including LMP1.
LMP1 is an oncogene, and expression of this protein
in transgenic mice results in B-cell lymphoma [22,23].
Infection of B cells in vitro by EBV results in latent
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infection and immortalization of the cells. In vivo, the
cellular immune response (NK cells and CD4 and
CD8 cytotoxic T cells) controls proliferating EBV-
infected B cells during primary infection and during
reactivation. In patients with impaired T-cell immu-
nity from conditions such as congenital immunodeﬁ-
ciencies and acquired immunodeﬁciency syndrome or
after solid organ transplantation or HSCT, the T cells
may be unable to control the proliferation of EBV-
infected cells.
EBV-PTLD may initially manifest as a limited or
extensive polyclonal or monoclonal disease. If EBV-
PTLD is extensive and monoclonal at diagnosis, it
may have a rapidly progressive course with a fatal
outcome, as in the 2 patients described in this study.
EBV-PTLD has an overall incidence of 1.0% after
allogeneic HSCT and may be as high as 18%-25% in
certain subsets of patients but is only rarely described
after autologous HSCT [1]. Risk factors associated
with the development of EBV-PTLD after allogeneic
HSCT are those that are known to be associated with
inducing a higher degree of immunosuppression, in-
cluding T-cell depletion of the stem cell grafts or
intensiﬁcation of immunosuppression with T cell–
speciﬁc agents to control graft-versus-host disease
[24-26]. Seventeen cases of EBV-PTLD after autolo-
gous HSCT have been identiﬁed in the literature
[1-4,6-8,27,28] (Table 4). Nine of these cases (mostly
the earlier case reports) were after marrow transplan-
tation, and 8 were after transplantation with PBSC.
Twelve of the cases had some type of graft manipula-
tion, including CD34 selection (n  6), T-cell deple-
tion (n  3), or purging with an alkylating agent (n 
2). One patient with non-Hodgkin lymphoma had a
graft that was B-cell depleted. All of the cases of
EBV-PTLD except 2 had onset before day 100 after
transplantation. Seven of the 17 cases remitted with
treatment. None of the reported cases were treated for
autoimmune diseases or received ATG in combina-
tion with the high-dose chemoradiotherapy. Although
an interpretation of the case reports is limited by the
selected nature of the reporting, the risk factors asso-
ciated with the development of EBV-PTLD after au-
tologous HSCT may relate to the underlying immune
status at the time of the stem cell harvest secondary to
more intensive pretransplantation chemotherapy or
T-cell depletion (including CD34 selection) of the
graft.
As after allogeneic HSCT, use of a T cell–de-
pleted autologous graft after high-dose chemoradio-
therapy may result in a more immunosuppressed state
and a higher incidence of transplant-related compli-
cations [29]. Although the experience was small, there
seemed to be a higher risk of Pneumocystis carinii pneu-
monia and CMV reactivation after transplantation
with T cell-depleted or CD34-selected autologous
grafts [27]. The B-cell origin of the EBV-PTLD when
it occurs after allogeneic HSCT is normally donor
derived and, therefore, is arising from the graft. Be-
cause EBV-PTLD after autologous HSCT has oc-
curred after CD34 selection (3-log B-cell depletion)
and B-cell depletion of the graft, the malignant B-cell
population may derive from residual B cells that have
survived the high-dose chemoradiotherapy [3,4,6,8].
The standard form of ATG used in the HDIT
regimen used in this report was equine ATG. If pa-
tients had a positive skin test or had an adverse reac-
tion during the infusion of equine ATG, rabbit ATG
was used instead. Rabbit ATG is a very effective im-
munosuppressive agent and has been safely used at
doses of 10.5-21 mg/kg for the treatment of rejection
after kidney transplantation (most patients received
rabbit ATG at the dose of 15 mg/kg) [30]. The use of
rabbit ATG in that study was associated with a signif-
Table 3. EBV-PTLD after HDIT*
Variable
Patients
1† 2† 3† 4† 5-56 (n  52)
Total rabbit ATG dose (mg/kg) 12.5 15.0 10 10 0
Total equine ATG dose (mg/kg) 0 0 30 30 90 (0-90)‡
EBV-PTLD Yes Yes No No None
Disease from other opportunistic
infection in first 60 days HSV1 CMV No No 1 (HSV2)
Flow cytometry studies (day 28) (n  40)
CD3 cells/L§ 0 0 0 0 174 (16-4371)
B cells/L§ 47.3 0.4 1.0 8.1 2 (0-53.8)
NK cells/L§ 109 108 510 1401 301 (51-1401)
HSV indicates herpes simplex virus.
*CD3 T cells on day 28 after autologous HSCT were signiﬁcantly fewer in patients who received rabbit ATG (P  .001; Mann-Whitney
ranked sum test).
†Patients who received rabbit ATG with or without equine ATG.
‡Fifty patients had 90 mg/kg of equine ATG.
§Day 28 counts in peripheral blood; median (range).
R. A. Nash et al.
588
icantly greater degree of T-cell depletion, as well as a
more prolonged depletion of T cells than equine
ATG. There are reports in the literature of rabbit
ATG being associated with the development of EBV-
PTLD after allogeneic HSCT when it was used for
the treatment of graft-versus-host disease [31]. In this
report, only patients treated with rabbit ATG had
signiﬁcant complications secondary to reactivated her-
pes infection, EBV-PTLD, and absent circulating T
cells at day 30. This is likely related to the more potent
immunosuppressive effects of this biologic agent.
EBV-speciﬁc cellular immunity is important for
the prevention of EBV reactivation and EBV-PTLD
after HSCT [32]. This is similar to studies in which it
was demonstrated that the recovery of a CMV-speciﬁc
HLA class 1–restricted CD8 cytotoxic T lymphocyte
response was critical for protection from severe CMV
disease [33-35]. Recovery of the EBV cellular immune
response after high-dose chemoradiotherapy and au-
tologous HSCT for non-Hodgkin lymphoma oc-
curred between 8 and 12 weeks after autologous trans-
plantation with a PBSC graft [36]. This may be
signiﬁcantly delayed with CD34 selection of the graft
and in vivo T-cell depletion with ATG. Reconstitu-
tion of the EBV cellular immune response by infusion
of unselected donor lymphocytes or donor-derived
EBV-speciﬁc cytotoxic T lymphocytes is effective for
the prevention of EBV reactivation or the treatment
of EBV-PTLD [37-40]. However, the use of donor-
derived lymphocytes would not have a role for pa-
tients after autologous transplantation. The use of B
cell–speciﬁc antibodies as prophylaxis or as preemp-
tive therapy after EBV reactivation is likely to be a
more appropriate therapy for patients after autologous
transplantation [41,42]. However, neither the infusion
of backup autologous PBSC in 1 patient nor the ad-
ministration of rituximab to both patients prevented
the fatal outcome in this study.
Profound immunosuppression can be induced in
patients with severe autoimmune diseases after HDIT
with ATG and transplantation with autologous
CD34-selected hematopoietic stem cells. Rabbit ATG
at a total dose of 10.0 to 15.0 mg/kg was more immu-
nosuppressive than equine ATG at a total dose of 90
mg/kg and was associated with the development of
EBV-PTLD. Even if EBV-PTLD could be pre-
vented, the severity of the immunosuppression in-
duced by this dose of rabbit ATG (in the context of
chemoradiotherapy plus CD34-selected autologous
grafts) would likely increase the risk of developing
other severe opportunistic infections. Our studies
were not designed to identify a safe dose or schedule
of rabbit ATG, so subsequent patients on the study
did not receive any ATG if they had a positive skin test
or an intolerable infusion reaction to equine ATG.
Caution is required in any attempts to further inten-
sify the immunosuppressive effects of HDIT with
other agents speciﬁc for T cells, especially if grafts are
T-cell depleted or CD34 selected. Routine monitor-
ing for EBV reactivation and preemptive therapy with
rituximab if high levels of EBVDNA are detected may
be required for some HDIT regimens. Until the im-
Table 4. EBV-PTLD after Autologous HSCT: Case Reports
Study
Year of
Publication
No.
Patients Disease
Source of
Stem Cells
Graft
Manipulation
Time of
EBV-PTLD
Onset
after
HSCT Outcome
Anderson et al. [27] 1990 2 1 T-NHL Marrow T-depl. 31, 42 d Fatal, resolved (died later
from PCP)1 T-NHL
Chao et al. [3] 1993 1 NHL Marrow B-depl. 47 d Fatal
Shepherd et al. [7] 1995 1 CML Marrow Ex vivo culture
( 10 d)
33 d Resolved
Briz et al. [4] 1997 1 T-ALL Marrow T-depl. 60 d Fatal
Hauke et al. [2] 1998 2 1 HD Marrow None 38, 87 d Fatal (2)
1 NHL
Peniket et al. [6] 1998 1 MM PBSC CD34 selected 63 d Fatal
McCaul et al. [1] 1999 3 2 MM Marrow 4-HC <80 d Fatal (3)
(4)* 1 NHL Marrow Mafosfamide <80 d
1 CML PBSC None 31 mo
Powell et al. [8] 2002 5 Neuroblastoma PBSC CD34 selected Median, 3
(range,
1-5) mo
Fatal (1), resolved (4)
Heath et al. [28] 2002 1 Retinoblastoma PBSC None 21 d Resolved
4-HC indicates 4-hydroperoxycyclophosphamide; B-depl, B-cell depletion; CML, chronic myelogenous leukemia; EBV-PTLD, Epstein-Barr
virus-associated posttransplantation lymphoproliferative disorder; HD, Hodgkin disease; HSCT, hematopoietic stem cell transplantation;
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cells; PCP, Pneumocystis carinii pneumonia;
T-ALL, T-cell acute lymphocytic leukemia; T-depl., T-cell depletion; T-NHL, T-cell non-Hodgkin lymphoma.
*One case had been previously reported.
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munosuppressive differences between equine and rab-
bit ATG are further deﬁned, these biologic agents
should not be considered interchangeable in HDIT
regimens.
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